Senti Biosciences Aktie - SNTI

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

3,01

Gebot

1,52

Fragen

5,00

Volumen

256.400

2,63 Tagesbereich 3,77

1,5201 52-Wochen-Bereich 16,94

Marktkapitalisierung

13,812M

Handelsende

3,66

Handelsbeginn

3,66

Letzte Trade

3.18

Letzter Handelszeitpunkt

Finanzvolumen

US$ 766.213

VWAP

2,9884

Durchschnittliches Volumen (3 Mio.)

103.576

Ausgegebene Aktien

4.588.645

Dividendenrendite

Kurs-Gewinn-Verhältnis

-0,20

Gewinn pro Aktie (EPS)

-15,49

Erlöse

2,56M

Nettogewinn

-71,06M

Senti Biosciences Inc is engaged in creating new generation smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti Biosciences Inc is engaged in creating new generation smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches.

Sektor

Biological Pds,ex Diagnstics

Branche

Biological Pds,ex Diagnstics

Website

www.sentibio.com

Hauptsitz

Wilmington, Delaware, USA

Gegründet

Senti Biosciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker SNTI. The last closing price for Senti Biosciences was US$3,66. Over the last year, Senti Biosciences shares have traded in a share price range of US$ 1,5201 to US$ 16,94.

Senti Biosciences currently has 4.588.645 shares in issue. The market capitalisation of Senti Biosciences is US$16,79 million. Senti Biosciences has a price to earnings ratio (PE ratio) of -0.20.

Senti Bio Strengthens Leadership Team with Strategic Hires

– Jay Cross, proven financial leader, appointed as CFO to drive strategic growth – – Faraz Siddiqui, expert in...

Form DEF 14A - Other definitive proxy statements

Senti Bio Announces Additional $11.5 Million of Financing

– Approximately $10 million additional investment in private placement equity financing – – $1.5 million from...

Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics

– Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of...

Senti Biosciences Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI...

Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti...

Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML

– 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.97	-24.3718592965	3.98	4.0899	3.02	26939	3.7839209	CS
4	-1.45	-32.5112107623	4.46	4.5553	3.02	26205	4.05885087	CS
12	-2.99	-49.8333333333	6	7.1	3.02	103576	4.85045594	CS
26	0.29	10.6617647059	2.72	16.94	2	1164293	9.54608611	CS
52	-1.35	-30.9633027523	4.36	16.94	1.5201	2434882	5.3181367	CS
156	-71.69	-95.9705488621	74.7	87.7	1.5201	1798700	14.78028362	CS
260	-71.69	-95.9705488621	74.7	87.7	1.5201	1798700	14.78028362	CS

SNTI - Frequently Asked Questions (FAQ)

What is the current Senti Biosciences share price?

The current share price of Senti Biosciences is US$ 3,01

How many Senti Biosciences shares are in issue?

Senti Biosciences has 4.588.645 shares in issue

What is the market cap of Senti Biosciences?

The market capitalisation of Senti Biosciences is USD 16,79M

What is the 1 year trading range for Senti Biosciences share price?

Senti Biosciences has traded in the range of US$ 1,5201 to US$ 16,94 during the past year

What is the PE ratio of Senti Biosciences?

The price to earnings ratio of Senti Biosciences is -0,2

What is the cash to sales ratio of Senti Biosciences?

The cash to sales ratio of Senti Biosciences is 5,41

What is the reporting currency for Senti Biosciences?

Senti Biosciences reports financial results in USD

What is the latest annual turnover for Senti Biosciences?

The latest annual turnover of Senti Biosciences is USD 2,56M

What is the latest annual profit for Senti Biosciences?

The latest annual profit of Senti Biosciences is USD -71,06M

What is the registered address of Senti Biosciences?

The registered address for Senti Biosciences is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Senti Biosciences website address?

The website address for Senti Biosciences is www.sentibio.com

Which industry sector does Senti Biosciences operate in?

Senti Biosciences operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
STAKSTAK Inc	US$ 3,97 (156,13%)	174,23k
ORGOOrganogenesis Holdings Inc	US$ 6,21 (102,28%)	59M
TRNRInteractive Strength Inc	US$ 2,57 (67,97%)	193,57M
PMAXPowell Max Ltd	US$ 0,511 (43,54%)	137,18M
ARBBARB IOT Group Ltd	US$ 0,6635 (38,23%)	59,08M
NVNINVNI Group Ltd	US$ 0,99 (-50,50%)	72,79M
SPGCSacks Parente Golf Inc	US$ 0,2085 (-48,65%)	58,21M
ADGMAdagio Medical Holdings Inc	US$ 0,8081 (-47,53%)	756,76k
PRAXPraxis Precision Medicines Inc	US$ 38,60 (-40,64%)	3,2M
SAGSAG Holdings Ltd	US$ 1,19 (-38,97%)	789,86k
NVDANVIDIA Corporation	US$ 124,92 (3,97%)	389,48M
TRNRInteractive Strength Inc	US$ 2,57 (67,97%)	193,57M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 13,44 (7,78%)	154,46M
PMAXPowell Max Ltd	US$ 0,511 (43,54%)	137,18M
LCIDLucid Group Inc	US$ 2,22 (-0,45%)	136,17M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Senti Biosciences Inc (SNTI)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Senti Biosciences Inc

SNTI Neueste Nachrichten

Senti Bio Strengthens Leadership Team with Strategic Hires

Form DEF 14A - Other definitive proxy statements

Senti Bio Announces Additional $11.5 Million of Financing

Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics

Senti Biosciences Announces New Employment Inducement Grants

Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing

Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML

Senti Bio Appoints Fran Schulz to Board of Directors

Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights

Senti Bio to Participate in Upcoming Investor Conferences

Senti Bio Strengthens Leadership Team with Strategic Hires

Form DEF 14A - Other definitive proxy statements

Senti Bio Announces Additional $11.5 Million of Financing

Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics

Senti Biosciences Announces New Employment Inducement Grants

Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing

Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML

Senti Bio Appoints Fran Schulz to Board of Directors

SNTI - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Senti Biosciences Inc (SNTI) Börsenkurse

Senti Biosciences Inc (SNTI)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Senti Biosciences Inc

SNTI Neueste Nachrichten

Senti Bio Strengthens Leadership Team with Strategic Hires

Form DEF 14A - Other definitive proxy statements

Senti Bio Announces Additional $11.5 Million of Financing

Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics

Senti Biosciences Announces New Employment Inducement Grants

Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing

Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML

Senti Bio Appoints Fran Schulz to Board of Directors

Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights

Senti Bio to Participate in Upcoming Investor Conferences

Senti Bio Strengthens Leadership Team with Strategic Hires

Form DEF 14A - Other definitive proxy statements

Senti Bio Announces Additional $11.5 Million of Financing

Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics

Senti Biosciences Announces New Employment Inducement Grants

Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing

Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML

Senti Bio Appoints Fran Schulz to Board of Directors

SNTI - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen